- Home
- USCB vs ABEO Comparison
USCB vs ABEO Comparison
Compare USCB & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- ABEO
- Stock Information
- Founded
- USCB 2002
- ABEO 1974
- Country
- USCB United States
- ABEO United States
- Employees
- USCB N/A
- ABEO N/A
- Industry
- USCB Major Banks
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- USCB Finance
- ABEO Health Care
- Exchange
- USCB Nasdaq
- ABEO Nasdaq
- Market Cap
- USCB 316.4M
- ABEO 256.9M
- IPO Year
- USCB 2021
- ABEO 1980
- Fundamental
- Price
- USCB $17.00
- ABEO $5.89
- Analyst Decision
- USCB Buy
- ABEO Strong Buy
- Analyst Count
- USCB 3
- ABEO 6
- Target Price
- USCB $20.50
- ABEO $18.00
- AVG Volume (30 Days)
- USCB 27.3K
- ABEO 1.1M
- Earning Date
- USCB 07-24-2025
- ABEO 08-11-2025
- Dividend Yield
- USCB 2.37%
- ABEO N/A
- EPS Growth
- USCB 78.48
- ABEO N/A
- EPS
- USCB 1.39
- ABEO N/A
- Revenue
- USCB $84,457,000.00
- ABEO N/A
- Revenue This Year
- USCB $23.28
- ABEO N/A
- Revenue Next Year
- USCB $7.02
- ABEO $323.51
- P/E Ratio
- USCB $12.23
- ABEO N/A
- Revenue Growth
- USCB 34.16
- ABEO N/A
- 52 Week Low
- USCB $11.88
- ABEO $3.93
- 52 Week High
- USCB $21.86
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- USCB 59.43
- ABEO 48.03
- Support Level
- USCB $16.08
- ABEO $5.49
- Resistance Level
- USCB $17.80
- ABEO $6.11
- Average True Range (ATR)
- USCB 0.45
- ABEO 0.28
- MACD
- USCB 0.13
- ABEO -0.04
- Stochastic Oscillator
- USCB 64.09
- ABEO 47.06
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.